Syndax Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, announced the issuance of inducement awards on June 1, 2025, under its 2023 Inducement Plan. The awards allow eight new employees to purchase up to 119,700 shares of common stock. The stock options will vest over four years, with 25% vesting on the first anniversary of the vesting commencement date, and the remaining shares vesting in equal monthly installments over the following 36 months. These terms are contingent on the employees maintaining their service relationship with the company through the respective vesting dates.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。